| Robert A Mittra, MD | |
|
7760 France Ave S, Suite 310, Minneapolis, MN 55435-5800 | |
| (952) 929-1131 | |
| (952) 897-1178 |
| Full Name | Robert A Mittra |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 28 Years |
| Location | 7760 France Ave S, Minneapolis, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699764456 | NPI | - | NPPES |
| 717645700 | Medicaid | MN | |
| 32448600 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 42976 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vitreo Retinal Surgery Pa | 6709899768 | 21 |
News Archive
For weeks a white powder caused fear and shock for the American population: a few days after the attacks on September 11th, 2001, four innocent people became the victims of letters that contained the powder - spores of the anthrax pathogen. German researchers have now synthesized a molecule characteristic of anthrax in the laboratory which may be the basis for a new anthrax vaccine.
An international team of scientists has discovered extensive similarities between a strain of bacteria commonly associated with plants and one increasingly linked to opportunistic infections in hospital patients. The findings suggest caution in the use of the plant-associated strain for a range of biotech applications. The genetic analysis was conducted in part at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, and will be published in the July 2009 issue of Nature Reviews Microbiology, now available online.
TBI/Tissue Banks International, Inc. today announced it has developed an Ocular Services Division to replace the Tissue Distribution and Information Center at the organization.
Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).
A cup of black tea could be the next line of defence in the threat of bio-terrorism according to new international research.
› Verified 3 days ago
| Entity Name | Vitreo Retinal Surgery Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891783965 PECOS PAC ID: 6709899768 Enrollment ID: O20060718000015 |
News Archive
For weeks a white powder caused fear and shock for the American population: a few days after the attacks on September 11th, 2001, four innocent people became the victims of letters that contained the powder - spores of the anthrax pathogen. German researchers have now synthesized a molecule characteristic of anthrax in the laboratory which may be the basis for a new anthrax vaccine.
An international team of scientists has discovered extensive similarities between a strain of bacteria commonly associated with plants and one increasingly linked to opportunistic infections in hospital patients. The findings suggest caution in the use of the plant-associated strain for a range of biotech applications. The genetic analysis was conducted in part at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, and will be published in the July 2009 issue of Nature Reviews Microbiology, now available online.
TBI/Tissue Banks International, Inc. today announced it has developed an Ocular Services Division to replace the Tissue Distribution and Information Center at the organization.
Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).
A cup of black tea could be the next line of defence in the threat of bio-terrorism according to new international research.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert A Mittra, MD 7760 France Ave S, Suite 310, Minneapolis, MN 55435-5800 Ph: (952) 929-1131 | Robert A Mittra, MD 7760 France Ave S, Suite 310, Minneapolis, MN 55435-5800 Ph: (952) 929-1131 |
News Archive
For weeks a white powder caused fear and shock for the American population: a few days after the attacks on September 11th, 2001, four innocent people became the victims of letters that contained the powder - spores of the anthrax pathogen. German researchers have now synthesized a molecule characteristic of anthrax in the laboratory which may be the basis for a new anthrax vaccine.
An international team of scientists has discovered extensive similarities between a strain of bacteria commonly associated with plants and one increasingly linked to opportunistic infections in hospital patients. The findings suggest caution in the use of the plant-associated strain for a range of biotech applications. The genetic analysis was conducted in part at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, and will be published in the July 2009 issue of Nature Reviews Microbiology, now available online.
TBI/Tissue Banks International, Inc. today announced it has developed an Ocular Services Division to replace the Tissue Distribution and Information Center at the organization.
Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).
A cup of black tea could be the next line of defence in the threat of bio-terrorism according to new international research.
› Verified 3 days ago
Dr. Morgan Leigh Pansegrau, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1 Veterans Dr, Va Ophthalmology, Minneapolis, MN 55417 Phone: 612-467-1100 Fax: 612-727-5972 | |
Sasha Strul, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 701 25th Ave S Ste 300, Minneapolis, MN 55454 Phone: 612-365-6777 | |
Huda Sheheitli, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 516 Delaware St Se, Minneapolis, MN 55455 Phone: 612-672-7422 | |
Alisha Kamboj, Ophthalmology Medicare: Medicare Enrolled Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 612-625-4400 | |
Guneet Singh Sodhi, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3601 W 76th St Ste 300, Minneapolis, MN 55435 Phone: 952-929-1131 | |
Edwin H Ryan Jr., MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7760 France Ave S, Suite 310, Minneapolis, MN 55435 Phone: 952-929-1131 Fax: 952-897-1178 | |
Dr. Dinesh K Goyal, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 825 Nicollet Mall, Ste 2000, Minneapolis, MN 55402 Phone: 612-338-4861 Fax: 612-333-8306 |